Genzyme Corp. announced that it will build a major new research and development center in Beijing. The initiative is an important element in Genzyme's ongoing global expansion and commitment to establishing a long-term presence in China. The new facility will be used for research and devel ... more
Genzyme Announces Agreement to Sell Genetic Testing Business to LabCorp
15-09-2010: Genzyme Corporation announced that it has entered into an asset purchase agreement under which Laboratory Corporation of America Holdings (LabCorp) will acquire Genzyme Genetics for $925 million in cash.
Under the terms of the agreement, LabCorp will purchase the business in its entirety, including all testing services, technology, intellectual property rights, and its nine testing laboratories. LabCorp is committed to offer employment to the unit’s approximately 1900 employees upon closing, including senior management. The agreement is subject to customary closing conditions, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976, with the goal of closing before the end of the year.
“This transaction demonstrates the strategic value of Genzyme Genetics and the strong franchise we’ve built over a twenty year period,” said Henri A. Termeer, chairman and chief executive officer of Genzyme Corporation. “It also shows how our management team is uniquely positioned to unlock the underappreciated value of Genzyme’s diverse businesses for shareholders. The completion of this sale allows us to focus our resources on core growth areas and create stronger returns on invested capital.”
Genzyme announced in May that it would seek strategic alternatives for three units as part of a five-part plan to increase shareholder value. The plan builds on the robust set of operational, organizational and board changes made over the past year to strengthen the company. Plans to divest the two other Genzyme business units, Diagnostic Products and Pharmaceutical intermediates, remain on track. Proceeds from these transactions may be used to finance the second half of the company’s $2 billion stock buyback to be completed by May 2011.
Genzyme Corporation announced the availability of its p53 Mutation Analysis for B-cell chronic lymphocytic leukemia (B-CLL). P53 is a tumor suppressor gene that stops cell division when DNA damage is present. When the p53 gene does not function normally, genetic mutations that can occur in ... more
Genzyme Corporation announced that it has entered into an asset purchase agreement under which Laboratory Corporation of America Holdings (LabCorp) will acquire Genzyme Genetics for $925 million in cash. Under the terms of the agreement, LabCorp will purchase the business in its entirety, ... more
OncoMethylome Sciences and Laboratory Corporation of America® Holdings (LabCorp®) announced that OncoMethylome has granted LabCorp an exclusive license on certain IP technology to perform commercial MGMT methylation laboratory testing services in the United States and Canada subject to limi ... more
- 1Nano-sized chip "sniffs out" explosives far better than trained dogs
- 2Malvern Instruments completes acquisitions
- 3Schleicher & Schuell has been purchased by Whatman plc
- 4Analytik Jena AG Signs Agreement to Acquire Bruker's ICP-MS Business
- 5Analytik Jena Closed Third Quarter Below Expectations
- 6Mettler Toledo installs Tunable Diode Lasers (TDLs) where no TDLs have gone before
- 7Synthesis of structurally pure carbon nanotubes using molecular seeds
- 8Malvern Instruments acquires assets of Reologica Instruments AB
- 9Bochem Increasingly Using New Media
- 10Danaher Announces Definitive Agreement to Acquire Leica Microsystems
- Messe München International takes over one of India's leading trade fairs fo ...
- A new ISO 9001:2008 for Altmann Analytik by TÜV Süd
- DKSH exclusively distributes Postnova Analytics’ Field-Flow Fractionation sy ...
- Analytik Jena AG Signs Agreement to Acquire Bruker's ICP-MS Business
- Bochem Increasingly Using New Media